Welcome to Glycotope

Targeting tumor-specific glycosylation patterns to enable advanced therapies

We are Glycotope

We are dedicated to improving the lives of cancer patients by enabling treatment options that go beyond today’s standard of care.

With exceptional experience in glycobiology and therapeutic antibody development, our mission is to develop advanced biologics that facilitate novel approaches to cancer therapies.

Setting new standards of tumor-specificity in antibody therapeutics

About Us

Learn More about Glycotope and our Leadership Team

Learn more

Technology

Our proprietary technology platform enables the development of antibodies with unrivaled tumor-specificity

Learn more

Pipeline

Our pipeline of antibody therapeutics includes in-house and partnered pre-clinical programs

Learn more

Partners

We aim to continuously expand our collaborations with industry partners and academic centers to further exploit the unique potential of our technology

Learn more

News

15. November 2021
Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting
Read Article
27. July 2021
Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets
Read Article
16. June 2021
Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
Read Article
Read All